WASHINGTON, March 5, 2019 /PRNewswire/ -- The Community Access National Network, otherwise known as CANN, today released a final report by its national commission, which was charged to take a thorough and candid review of the 340B Drug Pricing Program (hereafter referred to as 340B Program. The final report embodies a nearly year long review of the 340B Program and the issues spurring discussion, stakeholder stances and possible resolutions.
The 340B Program was created at a time when nonprofit healthcare providers were spending to ensure that patients had access to medicine to treat acute and chronic healthcare problems. Their goal then and today – help ensure that the patient's acute care problem did not become chronic. At the inception of the 340B program, the number of the uninsured were greater, many state Medicaid programs limited who was eligible, and access to free or subsidized medication programs was not as robust as it is today.
Today, 26 years later, the 340B program has grown in the number of people being served and the kinds of what providers allowed to participate in the program. It is important to underscore the value of the program in helping patients access medications at the most affordable cash price. Participation in the Program results in significant savings estimated to be 20% to 50% on the cost of pharmaceuticals Covered Entities. But like every federal program, as it ages in place, questions arise. The final report tackles those questions.
The 340B Commission's final report is available online to download at http://www.tiicann.org/admin_340b-commission.html.
About the Community Access National Network: The mission of the Community Access National Network (CANN) is to define, promote, and improve access to healthcare services and supports for people living with HIV/AIDS and/or Viral Hepatitis through advocacy, education, and networking. These services must be affordable to the people who need them regardless of insurance status, income, or geographic location.
This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.
Advertisement
The 340B Program was created at a time when nonprofit healthcare providers were spending to ensure that patients had access to medicine to treat acute and chronic healthcare problems. Their goal then and today – help ensure that the patient's acute care problem did not become chronic. At the inception of the 340B program, the number of the uninsured were greater, many state Medicaid programs limited who was eligible, and access to free or subsidized medication programs was not as robust as it is today.
Advertisement
Today, 26 years later, the 340B program has grown in the number of people being served and the kinds of what providers allowed to participate in the program. It is important to underscore the value of the program in helping patients access medications at the most affordable cash price. Participation in the Program results in significant savings estimated to be 20% to 50% on the cost of pharmaceuticals Covered Entities. But like every federal program, as it ages in place, questions arise. The final report tackles those questions.
The 340B Commission's final report is available online to download at http://www.tiicann.org/admin_340b-commission.html.
About the Community Access National Network: The mission of the Community Access National Network (CANN) is to define, promote, and improve access to healthcare services and supports for people living with HIV/AIDS and/or Viral Hepatitis through advocacy, education, and networking. These services must be affordable to the people who need them regardless of insurance status, income, or geographic location.
This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.
View original content:http://www.prnewswire.com/news-releases/community-access-national-networks-340b-commission-releases-final-report-300806454.html
SOURCE Community Access National Network
